Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1982-4-20
|
pubmed:abstractText |
The antineoplastic activity of vindesine was evaluated in a phase II trial in patients with squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung. Sixty-three patients participated in the trial: 22 with squamous cell carcinoma, 25 with adenocarcinoma, and 16 with large cell carcinoma. Most of the patients had not received prior treatment; six had received single-agent chemotherapy. The dose of vindesine was 4 mg/m2 every 2 weeks, reduced or increased according to hematologic and neurologic side effects. Fifty-four patients were evaluable. Objective response was observed in two of 19 patients with squamous cell carcinoma (11%), in six of 22 patients with adenocarcinoma (27%), and in one of 13 patients with large cell carcinoma (8%). In patients with adenocarcinoma the median duration of response was 196 days (range, 71-450+). Twenty-five percent of the evaluable patients received greater than or equal to 100% of the scheduled dose. In 39% of the patients, dose reductions were necessary because of leukopenia, and in 63%, dose modifications were necessary because of neurotoxic effects. It is concluded that vindesine as a single-agent chemotherapy is active against adenocarcinoma of the lung. Activity in squamous cell carcinoma and large cell carcinoma appears to be less, but not totally absent.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0361-5960
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
66
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
305-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7055816-Adenocarcinoma,
pubmed-meshheading:7055816-Adult,
pubmed-meshheading:7055816-Aged,
pubmed-meshheading:7055816-Carcinoma,
pubmed-meshheading:7055816-Carcinoma, Squamous Cell,
pubmed-meshheading:7055816-Drug Evaluation,
pubmed-meshheading:7055816-Female,
pubmed-meshheading:7055816-Humans,
pubmed-meshheading:7055816-Lung Neoplasms,
pubmed-meshheading:7055816-Male,
pubmed-meshheading:7055816-Middle Aged,
pubmed-meshheading:7055816-Vinblastine,
pubmed-meshheading:7055816-Vindesine
|
pubmed:year |
1982
|
pubmed:articleTitle |
Vindesine in the treatment of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|